GL Pharm Tech

GL Pharm Tech is a KOSDAQ-listed pharmaceutical company whose core business is developing improved new drugs (incrementally modified drugs) using drug delivery system (DDS) technologies such as controlled release and absorption enhancement.

The company focuses on pharmaceutical R&D services and sales and marketing, co-developing products with various partners and applying its formulation research and clinical trial design experience to new drug candidate development.

In the second half of 2022 the company established a dedicated pharmaceutical sales and marketing division to diversify its customer base through ethical (ETC) drug sales agency work.

Its flagship product is Kabalin CR, a controlled-release improved formulation of pregabalin (a neuropathic pain treatment), alongside other products such as the anti-ulcer drug Jisolen.

Its formerly wholly owned subsidiary GL Pharma operated KGMP-certified hormone drug manufacturing facilities that few domestic pharmaceutical companies possess, and had expanded into contract manufacturing (CMO) services.

In July 2026, GL Pharm Tech absorbed GL Pharma through a no-new-shares, small-scale merger, unifying its sales and R&D organizations and consolidating redundant operations.

The company said the merger would allow it to apply for innovative pharmaceutical company status, which could bring benefits such as drug pricing preferences, tax incentives, and regulatory support.

Its pipeline also includes Recoflavone, a dry-eye disease treatment candidate co-developed with Aju Pharm, and GLA5PR, a once-daily pregabalin formulation under development.

In 2025, consolidated revenue reached KRW 35.27 billion, up roughly 35% from KRW 26.05 billion in 2024, marking a record high. Operating profit for the same period was KRW 268 million, turning positive from an operating loss of KRW 1.77 billion in 2024.

However, net income attributable to owners was only KRW 12.49 million, meaning the bottom-line contribution remained marginal despite the improvement in revenue and operating profit.

On a quarterly basis, 2025Q3 revenue was KRW 9.53 billion with operating profit of KRW 253 million and net income of KRW 133 million, continuing the improving trend, but 2025Q4 revenue held at a similar KRW 9.53 billion while operating profit reversed to a loss of KRW 294 million and net income fell to a loss of KRW 201 million.

In 2026Q1, revenue was KRW 9.43 billion with a slim operating profit of KRW 35 million, yet net income posted another loss of KRW 120 million. 2026Q2 saw improvement again, with revenue of KRW 9.70 billion, operating profit of KRW 231 million, and net income of KRW 82 million, underscoring a pattern of quarter-to-quarter swings.

As a result, the trailing four-quarter (2025Q3-2026Q2) sum of owners' net income remained negative at KRW -107 million.

Following three consecutive years of net losses in 2022 (KRW -790 million), 2023 (KRW -3.75 billion), and 2024 (KRW -2.34 billion), the marginal return to profit in 2025 suggests the stability of earnings is still in a validation phase.

Korea's improved-drug and DDS market operates in an environment where patent expirations on original drugs intensify generic competition, making formulation differentiation a key competitive barrier.

The pregabalin controlled-release market includes the original Lyrica CR alongside multiple generic competitors from Yuhan, LG Chem, Hanlim Pharm, and Daewon Pharm, with the overall pregabalin market estimated at around KRW 60 billion.

The domestic dry-eye disease treatment market is estimated at roughly KRW 480 billion according to UBIST data, with artificial tears (hyaluronic acid) accounting for about KRW 370 billion and cyclosporine and diquafosol each forming markets of roughly KRW 50 billion, while no domestically developed new drug currently exists in this space.

If Recoflavone enters this market, it could become the first domestically developed new drug for dry-eye disease, potentially altering the competitive landscape.

In contract manufacturing (CMO), GL Pharma's hormone drug production facilities provide some competitive edge, but competition persists from other domestic small and mid-sized CMO/ODM firms.

Overall, Korea's pharmaceutical industry faces structural pressures from drug price cuts and intensifying generic competition, leaving differentiation through new and improved products as an ongoing challenge.

The most important near-term event is the MFDS approval decision on Recoflavone. GL Pharma filed for approval on November 14, 2025, and under the agency's expedited review framework targeting completion within roughly 295 days, early September 2026 is cited as the point when the review deadline arrives.

The company has stated it aims to obtain approval as early as the second half of 2026, followed by price negotiations with the Health Insurance Review and Assessment Service, targeting a 2027 launch.

If approved, it would become Korea's first domestically developed dry-eye disease drug, and the company has also mentioned potential for overseas market expansion.

With the GL Pharma merger completed effective July 31, 2026, cost savings from unifying sales and R&D organizations and the potential to apply for innovative pharmaceutical company status have become the next points to monitor.

On the pipeline side, Phase 1 trials for GLA5PR, a once-daily pregabalin formulation, are underway, and Phase 1 for GL2702, a new formulation for benign prostatic hyperplasia treatment, has been completed, with follow-up progress requiring confirmation.

These timelines are based on company announcements and media reports, and actual approval, price listing, and revenue recognition dates may shift depending on regulatory procedures.